⌕
Cerus · CERS · Nasdaq
Tenet 33 · Weak
Compare
$1.86−6.30%At closeTenet 33 · Weak
$1.86−0.13 (−6.30%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Cerus (CERS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is CERS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Business WireNov 11, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that members of the Company's management will participate in and host one-on-one investor meetings at the 17th Annual Craig-Hallum Alpha …

CERS −6.3% todayRead at source ↗
● Defense WorldNov 11, 2026 · 01:15 ET
Cerus Corporation (NASDAQ:CERS) Stock Has Average Target Price of $5.25

Shares of Cerus Corporation (NASDAQ: CERS - Get Free Report) have been assigned a consensus recommendation of "Hold" from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One equities…

CERS −6.3% todayRead at source ↗
● Fool - Investing NewsNov 3, 2026 · 06:39 ET
Cerus: 3 Key Takeaways for Long-Term Investors

A shift to higher-margin kit distribution and a successful red blood cell trial position Cerus for path to GAAP profitability.…

CERS −6.3% todayRead at source ↗
● Seeking AlphaNov 3, 2026 · 03:45 ET
Cerus Corporation (CERS) Q3 2026 Earnings Call Transcript

Cerus Corporation ( CERS ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Timothy Lee - Head of Investor Relation Vivek Jayaraman - CEO, President & Director Kevin Green - VP of Finance & CFO Con…

CERS −6.3% todayRead at source ↗
● MarketBeatNov 2, 2026 · 19:14 ET
Cerus Q3 Earnings Call Highlights

Cerus NASDAQ: CERS reported third-quarter product revenue growth of 10% year over year and reaffirmed its 2026 revenue outlook, while also announcing positive top-line results from its Phase III RedeS study of pathogen-r…

CERS −6.3% todayRead at source ↗
● ReutersNov 2, 2026 · 16:26 ET
Cerus' blood-safety system meets main goal in late-stage trial

Cerus' blood-safety system meets main goal in late-stage trial…

CERS −6.3% todayRead at source ↗
● Business WireNov 2, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Cerus Corporation Announces Third Quarter 2026 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2026, and provided a business update. "Our solid performance in Q3 builds upo…

CERS −6.3% todayRead at source ↗
● Business WireNov 2, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced positive topline results from the Phase 3 RedeS (NCT03037164) trial. “Over the past decade, pathogen reduction technology has become an i…

CERS −6.3% todayRead at source ↗
● Business WireOct 19, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2026 financial results will be released on Monday, November 2, 2026, after the close of the stock market. The Comp…

CERS −6.3% todayRead at source ↗
● Business WireOct 14, 2026 · 16:30 ETCOMPANY'S OWN WORDS
Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen …

CERS −6.3% todayRead at source ↗
● Defense WorldSep 25, 2026 · 04:15 ET
RxSight (NASDAQ:RXST) & Cerus (NASDAQ:CERS) Critical Analysis

Cerus (NASDAQ: CERS - Get Free Report) and RxSight (NASDAQ: RXST - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of t…

CERS −6.3% todayRead at source ↗
● Seeking AlphaAug 18, 2026 · 10:34 ET
Cerus: This Blood-Safety Underdog Should Be Earning More Respect

Cerus (CERS) is pivoting toward higher-value therapeutic products while reducing its research cost burden, aided by substantial government funding. Q2 2026 results signal an inflection point: product revenue grew 10%, op…

CERS −6.3% todayRead at source ↗
● Defense WorldAug 16, 2026 · 04:19 ET
Assenagon Asset Management S.A. Has $920,000 Stock Holdings in Cerus Corporation $CERS

Assenagon Asset Management S.A. lessened its holdings in Cerus Corporation (NASDAQ: CERS) by 74.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange C…

CERS −6.3% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just CERS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.